Celltrion Shows Rat Data for CT-G32, a Four-Hormone Obesity Candidate It Says Beat Retatrutide at the Same Dose
Celltrion presented preclinical data at TIDES Europe in Amsterdam for CT-G32/SCO-940, developed with Japan's Scohia Pharma, which acts on GLP-1, GIP, glucagon, and amylin receptors, the Korea Herald reported on November 4. In diet-induced obese rats it produced more weight loss than retatrutide at the same dose, with less lean mass lost relative to total weight lost, though the company released no figures. Exposure data in primates support possible once-weekly dosing, and Celltrion plans to file an investigational new drug application with the FDA by February 2027.